Eli Lilly's Obesity Pill Shows Strong Initial Performance; OpenAI Launches New Drug Discovery AI Tool
Eli Lilly's obesity drug Foundayo has seen strong initial prescriptions, with 1,390 prescriptions written in its first week, though it lags behind Novo Nordisk's Wegovy. OpenAI introduced GPT-Rosalind, an AI model for life sciences research, which is being used by companies like Moderna and Amgen. Lilly's stock rose 2% following the news.
Tickers: $AMGN $GILD $JANX $LLY $MRNA $NVO $TMO
Topics: AI in healthcare drug discovery Eli Lilly Foundayo market performance obesity drug